The IDUA Knockout HCT 116 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HCT 116 human colorectal carcinoma cell line, engineered to disrupt the IDUA gene. This product provides a heterogeneous pool of edited cells with loss-of-function alleles, enabling the study of alpha-L-iduronidase (IDUA) deficiency without selecting for a single clonal genotype. The polyclonal format more closely reflects the genetic diversity of a disease-relevant cellular context, avoiding biases associated with monoclonal adaptation. This cell model serves as a versatile tool for investigating lysosomal storage disorder pathology, particularly mucopolysaccharidosis type I (MPS I), in a cancer-relevant epithelial background. Researchers can employ these cells for functional genomics, drug screening, and mechanistic pathway analysis.
The host HCT 116 cell line is a widely used colorectal carcinoma model derived from a male patient, characterized by microsatellite instability (MSI) due to a homozygous mutation in the MLH1 mismatch repair gene. These cells express wild-type p53 and harbor a KRAS G13D mutation, making them representative of a subset of colorectal tumors with defective DNA repair and active RAS signaling. As intestinal epithelial cells, HCT 116 cells maintain key features of colonic epithelium and are amenable to genetic manipulation, high-throughput screening, and xenograft studies. Their robust growth and well-documented signaling networks provide a consistent platform for examining gene function and therapeutic interventions. Combined with IDUA knockout, this background allows for the dissection of lysosomal biology and its interplay with cancer cell homeostasis.
The IDUA gene encodes alpha-L-iduronidase, a lysosomal enzyme essential for the stepwise degradation of the glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate. Loss of IDUA function prevents cleavage of terminal iduronic acid residues, leading to progressive GAG accumulation within lysosomes. Expression of IDUA is transcriptionally regulated by the master lysosomal biogenesis factor TFEB and is induced under nutrient deprivation and lysosomal stress conditions. The proenzyme is targeted to lysosomes via the mannose-6-phosphate receptor pathway, where it acts in concert with iduronate-2-sulfatase, heparan N-sulfatase, N-acetylglucosamine-6-sulfatase, and beta-glucuronidase to complete GAG catabolism. Thus, IDUA disruption initiates a cascade of lysosomal dysfunction, aberrant autophagy, and impaired turnover of sulfated glycosaminoglycans.
In the HCT 116 cellular context, IDUA knockout recapitulates key features of MPS I, including lysosomal enlargement, GAG storage, and secondary perturbations of autophagy and cellular metabolism. The well-defined MSI and KRAS mutant background allows researchers to explore potential crosstalk between lysosomal stress and oncogenic signaling pathways. For example, altered autophagy flux downstream of KRAS may exacerbate or modify the lysosomal storage phenotype, providing insights into cancer cell vulnerability under lysosomal challenge. This model thus supports the investigation of genotype-specific responses to enzyme replacement therapy or substrate reduction approaches, and may reveal synthetic lethal interactions exploitable in colorectal cancer.
Typical applications of this knockout model include lysosomal storage disease modeling, MPS I mechanistic studies, and preclinical evaluation of enzyme replacement therapies, pharmacological chaperones, or gene therapy vectors. These polyclonal cells are suitable for quantitative GAG accumulation assays using Alcian blue or dimethylmethylene blue methods, lysosomal enzyme activity measurements, western blotting and RT-qPCR for IDUA and associated factors, and immunofluorescence detection of lysosomal markers such as LAMP1 and LAMP2. Further analyses may encompass electron microscopy for ultrastructural visualization of storage inclusions, autophagy flux monitoring via LC3 turnover, and cell viability assessments under lysosomal stress induced by chloroquine or nutrient starvation. For additional information, please contact Ascent Research.
